You just read:

Polaryx Therapeutics Received Orphan Drug Designation From the European Medicines Agency (EMA) for the Treatment of Neuronal Ceroid Lipofuscinosis With PLX-200

News provided by

Polaryx Therapeutics, Inc.

Feb 26, 2018, 12:00 ET